Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | GMNN | O75496 | 1/20 | 0.43 |
| ▸ | PPM1B | O75688 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.43 |
| ▸ | TFPI2 | P48307 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | PPP5C | P53041 | 1/20 | 0.43 |
| ▸ | PPP1CA | P62136 | 1/20 | 0.43 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | THPO | P40225 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24084120 | 0.77 | FNTA (0.33) | — | |
| SCHEMBL15087028 | 0.77 | KDM4E (0.31) | KDM4EGMNNPPM1BLMNAPPP1CC | |
| SCHEMBL11278993 | 0.74 | PPM1B (0.39) | KDM4EGMNNPPM1BLMNAPPP1CC | |
| SCHEMBL24084126 | 0.74 | KDM4E (0.40) | KDM4EGMNNPPM1BLMNAPPP1CC | |
| SCHEMBL12291313 | 0.74 | FNTA (0.32) | — | |
| SCHEMBL27421570 | 0.73 | ALDH1A1 (0.33) | RAB9ASMN1; SMN2TDP1 | |
| SCHEMBL13891810 | 0.71 | LMNA (0.33) | KDM4EGMNNPPM1BLMNAPPP1CC | |
| SCHEMBL19658368 | 0.71 | LMNA (0.36) | KDM4ELMNARAB9APMP22CYP2D6 | |
| SCHEMBL18769019 | 0.71 | LMNA (0.36) | KDM4ELMNARAB9APMP22CYP2D6 | |
| SCHEMBL21475793 | 0.70 | LMNA (0.32) | KDM4EGMNNPPM1BLMNAPPP1CC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426639-B2 | Preparation of trans, trans muconic acid and trans, trans muconates | Amyris, Inc. (US) | 2013-04-23 | — | — | US | disclosed |
| US-20100314243-A1 | PREPARATION OF TRANS,TRANS MUCONIC ACID AND TRANS,TRANS MUCONATES | DRATHS CORPORATION (US) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100314243-A1 | PREPARATION OF TRANS,TRANS MUCONIC ACID AND TRANS,TRANS MUCONATES | MUC1, FUT6, ST6GAL1 | KDM4E 4877/4885GMNN 505/4885PPM1B 3821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.